Online inquiry

IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (CAT#: GTTS-WQ9585MR)

This product GTTS-WQ9585MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR&MET gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001346897.2; NM_000245.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1956; 4233
UniProt ID	Q504U8; P08581

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9585MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15993MR	IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ZTS-00521505
GTTS-WQ7619MR	IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	GEN1029
GTTS-WQ14383MR	IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	r-hTBP-1
GTTS-WQ2554MR	IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	AMG 477
GTTS-WQ7850MR	IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	GSK-1223249
GTTS-WQ12683MR	IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	OMP-21M18
GTTS-WQ7343MR	IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	FPA-150
GTTS-WQ15214MR	IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	TACI-Fc

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.